Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
About this item
Full title
Author / Creator
Ataga, Kenneth I , Kutlar, Abdullah , Kanter, Julie , Liles, Darla , Cancado, Rodolfo , Friedrisch, João , Guthrie, Troy H , Knight-Madden, Jennifer , Alvarez, Ofelia A , Gordeuk, Victor R , Gualandro, Sandra , Colella, Marina P , Smith, Wally R , Rollins, Scott A , Stocker, Jonathan W and Rother, Russell P
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this yearlong trial involving patients with sickle cell disease, crizanlizumab, an antibody to P-selectin, was associated with a 45% lower rate of pain crises than placebo and a longer time to their onset. Adverse events included arthralgia, diarrhea, and pruritus.
Sickle cell disease is characterized by the presence of sickle hemoglobin (HbS...
Alternative Titles
Full title
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5481200
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5481200
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1611770
